New Jer­sey biotech plans for tiny IPO; Vir gets $10M Gates Foun­da­tion grant for HIV vac­cine

Chro­mo­cell Ther­a­peu­tics, based in North Brunswick, New Jer­sey, plans to go pub­lic, ac­cord­ing to an SEC fil­ing.

Ac­cord­ing to its LinkedIn, Chro­mo­cell works in drug dis­cov­ery as well as fla­vor de­vel­op­ment. Years ago, the biotech li­censed out a pain can­di­date to Astel­las for $15 mil­lion up­front. — Lei Lei Wu

This sec­tion was cor­rect­ed to re­move an in­ac­cu­rate ref­er­ence to the SEC fil­ing of how much Chro­mo­cell will raise from its IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.